USA flag logo/image

An Official Website of the United States Government

Image-Guided High-Intensity Interstitial Ultrasound for Thermal Ablation of…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89482
Program Year/Program:
2008 / STTR
Agency Tracking Number:
CA121740
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ACOUSTIC MEDSYSTEMS, INC.
208 Burwash Avenue Savoy, IL 61874-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Image-Guided High-Intensity Interstitial Ultrasound for Thermal Ablation of Uteri
Agency: HHS
Contract: 1R41CA121740-01A2
Award Amount: $149,948.00
 

Abstract:

DESCRIPTION (provided by applicant): High-Intensity Interstitial Ultrasound for Thermal Ablation of Uterine Fibroids. Benign uterine tumors (fibroids) are clinically apparent in up to 50% of women and typically require surgical removal of symptomatic fibr oids or hysterectomy. Treatment options for women considering bearing children are limited to the invasive surgical open myomectomy to best maintain structural integrity of the uterine wall; the less invasive laparoscopic removal is contraindicated. There remains a substantial clinical need for a minimally-invasive alternative to traditional surgical approaches with the promise of less morbidity and recovery time, faster procedure time, and lower cost. Recent clinical investigations of minimally-invasive th ermal techniques (cryotherapy, thermal ablation) have demonstrated significant potential in reducing fibroid volume and related symptoms, while preserving uterine wall integrity. Some limitations of these techniques include an inability to spatially contro l the distribution of energy output to conform to the fibroid volume, inadequate single treatment volumes requiring multiple device insertions, long procedural times, or use may be limited by the proximity of a fibroid to critical tissue structures. Inters titial ultrasound devices are an innovative technology under development by our group for delivering thermal therapy for treating cancer and prostate BPH, with demonstrated capabilities to provide dynamic spatial control of selective heating patterns, grea ter radial thermal penetration, and fast heating times. We propose to develop this ultrasound technology specifically for the treatment of uterine fibroids; this technology has potential to provide a superior minimally-invasive heating technique for treati ng uterine fibroids with the promise of more accurate and thorough targeting, protection of critical non-targeted tissue (e.g., bladder, bowel), more accessibility to a larger number of fibroids, and faster procedure times. The objective of this STTR Phase I research plan is to extend existing technology and develop new interstitial ultrasound applicator designs with high-power output, temperature/dose feedback, and spatial control capabilities specific for conformal thermal ablation of large volumes requir ed for successful treatment of uterine fibroids. Empirical design, bench experiments, biothermal and acoustic modeling, together with experimental testing in human uterine fibroid tissue will be used for design feedback and to characterize device performan ce, as well as assess the technical and potential clinical feasibility. These results will be applied to the conceptual development and understanding of potential treatment approaches in preparation for the ultimate goal of product development and clinical implementation during Phase II. Project Narrative (Relevance). Benign uterine fibroid tumors affect millions of women each year in the U.S. (and around the world), and are the cause of more than half of the 600,000 hysterectomies performed annually in the U.S. There is a true clinical need for effective therapy with improved quality of life that is more favorable than existing treatment options. Direct costs for fibroid treatments exceed 2 billion annually in the U.S. The estimated prevalence of uterine f ibroids is 25-50% of women of reproductive age (target age range: 25-54 years old), corresponding to 16-32 million women in the U.S. There are nearly 2 million new cases diagnosed each year. Many women who wish to retain their uterus undergo a major surgic al procedure to treat their fibroids. Currently, the only minimally-invasive treatment is uterine artery embolization, which has significant side effects that go beyond the uterus and are also not an option for women who desire future childbearing due to t he vascular changes the embolization produces. The proposed new therapeutic ultrasound treatment would avoid major surgery for these women as well as allow

Principal Investigator:

Business Contact:


clifb@acousticmed.com
Small Business Information at Submission:

ACOUSTIC MEDSYSTEMS, INC.
ACOUSTIC MEDSYSTEMS, INC. 206 N RANDOLPH ST, STE 300 CHAMPAIGN, IL 61820

EIN/Tax ID: 371365835
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No